Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy

Malignant Solid Neoplasm Clinical Trial

Official title:

Rose Geranium in Sesame Oil Nasal Spray as an Agent to Improve Symptoms of Nasal Vestibulitis: A Phase III Double Blinded Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04620369
• Other study ID #: MC19C1
• Secondary ID: NCI-2020-08287
• Status: Completed
• Phase: Phase 3
• Start date: November 13, 2020
• Est. completion date: December 15, 2022

Study information

• Verified date: October 2023
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase III trial compares rose geranium in sesame oil nasal spray to isotonic nasal saline in improving symptoms of nasal vestibulitis in cancer patients receiving chemotherapy. Nasal (nose) symptoms (dryness, discomfort, bleeding, scabbing or sores) due to inflammation, termed nasal vestibulitis, is reported as a side effect of cancer-directed therapy. Rose geranium in sesame oil nasal spray may work better than isotonic nasal saline in improving symptoms of nasal vestibulitis.

Description:

PRIMARY OBJECTIVE:

I. To determine the ability of rose geranium in sesame oil nasal spray to alleviate nasal vestibulitis in patients undergoing systemic, antineoplastic therapy when compared with isotonic nasal saline.

SECONDARY OBJECTIVE:

I. To assess toxicities related to rose geranium in sesame oil nasal spray in this study situation.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril twice daily (BID) on days 1-14 in the absence of unacceptable toxicity.

ARM B: Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable toxicity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: December 15, 2022
• Est. primary completion date: December 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• REGISTRATION-INCLUSION CRITERIA

• Age >= 18 years and be diagnosed with cancer and receiving chemotherapy

• Ability to provide informed consent

• Willingness to complete questionnaires

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2

• One or more of the following nasal symptoms for which the patient reports they would appreciate treatment. Symptoms must have started after the initiation of systemic, antineoplastic therapies, be attributed to the systemic, antineoplastic therapies, and symptoms must be reported as being moderate (corresponding to a score of 2) or worse on a scale from mild (1) to very severe (4) on at least one of the items below.

• Dryness

• Discomfort/pain

• Bleeding

• Scabbing

• Sores

Exclusion Criteria:

• REGISTRATION-EXCLUSION CRITERIA

• Predisposition to epistaxis prior to the initiation of cancer-directed therapy (more than once a month over the previous year)

• Planned initiation or continuation of any topical nasal treatment other than the studied nasal spray,(such as nasal steroids, Ayr nasal gel, Neosporin ointment or nasal administration of petroleum jelly). Taking Imitrex for migraines is acceptable

• Previous exposure to rose geranium in sesame oil nasal spray

• Concurrent upper respiratory tract infection

• History of allergic or other adverse reactions to sesame oil or essential rose geranium oil

• Any other reason that the study clinician or investigator feels precludes safe or appropriate inclusion in this study

• Vulnerable populations: pregnant women, prisoners, mentally handicapped

• RE-REGISTRATION

• The patient will be un-blinded and determined to have been on the saline arm, when initially randomized

Related Conditions & MeSH terms

• Hematopoietic and Lymphoid Cell Neoplasm
• Malignant Solid Neoplasm
• Nasal Vestibulitis
• Neoplasms

Intervention

Drug:
• Placebo Administration
Instill isotonic nasal saline intranasally

Other:
• Questionnaire Administration
Ancillary studies

Drug:
• Rose Geranium in Sesame Oil Nasal Spray
Instill intranasally

Locations

Country	Name	City	State
United States	Mayo Clinic Health System in Albert Lea	Albert Lea	Minnesota
United States	Essentia Health Saint Joseph's Medical Center	Brainerd	Minnesota
United States	Essentia Health - Deer River Clinic	Deer River	Minnesota
United States	Essentia Health Saint Mary's - Detroit Lakes Clinic	Detroit Lakes	Minnesota
United States	Essentia Health Cancer Center	Duluth	Minnesota
United States	Essentia Health Ely Clinic	Ely	Minnesota
United States	Essentia Health - Fosston	Fosston	Minnesota
United States	Fairview Grand Itasca Clinic & Hospital	Grand Rapids	Minnesota
United States	Essentia Health Hibbing Clinic	Hibbing	Minnesota
United States	Fairview Range Medical Center	Hibbing	Minnesota
United States	Essentia Health - International Falls Clinic	International Falls	Minnesota
United States	Mayo Clinic Health Systems-Mankato	Mankato	Minnesota
United States	Monticello Cancer Center	Monticello	Minnesota
United States	Essentia Health - Park Rapids	Park Rapids	Minnesota
United States	Fairview Northland Medical Center	Princeton	Minnesota
United States	Mayo Clinic in Rochester	Rochester	Minnesota
United States	Essentia Health Sandstone	Sandstone	Minnesota
United States	Sanford Thief River Falls Medical Center	Thief River Falls	Minnesota
United States	Essentia Health Virginia Clinic	Virginia	Minnesota
United States	Sanford Cancer Center Worthington	Worthington	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response	Response is determined from a patient global impression of change scale and is defined as a patient reporting that the nasal symptom that was most prominent prior to starting the study has been moderately better or very much better 2 weeks after initiating the nasal spray. The number and percentage of patients experiencing a response 2 weeks after initiating the nasal spray will be estimated within each randomized arm and the corresponding two-sided 95% exact (Clopper-Pearson) confidence interval provided. A between-arm comparison of the proportion of patients experiencing a response 2 weeks after initiating the nasal spray will be made using the Fisher's exact test.	At 2 weeks after initiating the nasal spray
Secondary	Severity of most prominent nasal symptom indicated at baseline	For the most prominent nasal symptom indicated at baseline, patients will record the severity on an ordinal scale of 1=mild, 2=moderate, 3=severe, and 4=very severe. Two weeks after initiating the nasal spray the patients will record the severity of the most prominent nasal symptom as 0=none, 1=mild, 2=moderate, 3=severe, and 4=very severe. A shift table will be created to descriptively display the number of patients who record a 1, 2, 3, or 4 at baseline and the shift two-weeks after initiating the nasal spray. In addition, the within-patient change in severity of the most prominent nasal symptom will be calculated 2 weeks after initiating the nasal spray and summarized descriptively within each arm. The Wilcoxon rank-sum test will be performed, and the methods of Hodges and Lehmann will be applied to compute a point estimate and confidence interval for the difference in medians between the two arms.	Up to 2 weeks after initiating the nasal spray
Secondary	Nasal symptom analysis	Each nasal symptom (dryness, pain, bleeding, and scabbing) will be descriptively summarized, tabulated, and plotted according to arm at baseline, and at 1 and 2 weeks post-baseline; additionally, will group patients according to baseline severity for each symptom and summarize changes over time and according to arm. Shift tables will also be generated to descriptively display the number of patients who record a 1, 2, 3, or 4 at baseline and the shift one- and two-weeks after initiating the nasal spray.	Up to 2 weeks after initiating the nasal spray
Secondary	Incidence of adverse events (AEs)	The constellation of AEs as scored using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 will be summarized within arms by reporting the number and percentage of patients. Specifically, to evaluate the AE profiles associated with each arm, the maximum grade for each type of AE will be recorded for each patient and frequency tables will be reviewed to determine overall patterns and compared between arms using Wilcoxon tests.	Up to 2 weeks after initiating the nasal spray